As pressure to reduce costs increases, CFOs have an opportunity to deepen their cross-functional influence and fortify their advisory role to the CEO and other C-suite leaders. Capitalizing on this ...
Patritumab Deruxtecan (HER3-DXd; MK-1022) in Non–Small Cell Lung Cancer After Platinum-Based Chemotherapy and Immunotherapy Many drugs in development continue to follow the historical drug development ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results